Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients
- PMID: 29288229
- PMCID: PMC5798660
- DOI: 10.1212/WNL.0000000000004853
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients
Erratum in
-
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.Neurology. 2018 Oct 16;91(16):765. doi: 10.1212/WNL.0000000000006483. Neurology. 2018. PMID: 30323078 Free PMC article. No abstract available.
Abstract
Objective: To characterize, among European and Han Chinese populations, the genetic predictors of maculopapular exanthema (MPE), a cutaneous adverse drug reaction common to antiepileptic drugs.
Methods: We conducted a case-control genome-wide association study of autosomal genotypes, including Class I and II human leukocyte antigen (HLA) alleles, in 323 cases and 1,321 drug-tolerant controls from epilepsy cohorts of northern European and Han Chinese descent. Results from each cohort were meta-analyzed.
Results: We report an association between a rare variant in the complement factor H-related 4 (CFHR4) gene and phenytoin-induced MPE in Europeans (p = 4.5 × 10-11; odds ratio [95% confidence interval] 7 [3.2-16]). This variant is in complete linkage disequilibrium with a missense variant (N1050Y) in the complement factor H (CFH) gene. In addition, our results reinforce the association between HLA-A*31:01 and carbamazepine hypersensitivity. We did not identify significant genetic associations with MPE among Han Chinese patients.
Conclusions: The identification of genetic predictors of MPE in CFHR4 and CFH, members of the complement factor H-related protein family, suggest a new link between regulation of the complement system alternative pathway and phenytoin-induced hypersensitivity in European-ancestral patients.
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures


Comment in
-
Genetic testing to prevent adverse reactions to antiepileptic drugs: Primum non nocere.Neurology. 2018 Jan 23;90(4):155-156. doi: 10.1212/WNL.0000000000004869. Epub 2017 Dec 29. Neurology. 2018. PMID: 29288230 No abstract available.
References
-
- Li X, Yu K, Mei S, et al. . HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res 2015;65:107–111. - PubMed
-
- Chung WH, Hung SI, Hong HS, et al. . Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486. - PubMed
-
- Man CB, Kwan P, Baum L, et al. . Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015–1018. - PubMed
-
- Lonjou C, Thomas L, Borot N, et al. . A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006;6:265–268. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials